1. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour.
- Author
-
Kölby, L., Bernhardt, P., Johanson, V., Schmitt, A., Ahlman, H., Forssell-Aronsson, E., Mäcke, H., and Nilsson, O.
- Subjects
SOMATOSTATIN ,RADIOTHERAPY ,THERAPEUTICS ,NEUROENDOCRINE tumors ,GASTROINTESTINAL hormones ,TUMOR growth ,CLINICAL medicine - Abstract
Somatostatin receptor (sstr)-mediated radiation therapy is a new therapeutic modality for neuroendocrine (NE) tumours. High expression of sstr in NE tumours leads to tumour-specific uptake of radiolabelled somatostatin analogues and high absorbed doses. In this study, we present the first optimised radiation therapy via sstr using [
177 Lu-DOTA0 -Tyr3 ]-octreotate given to nude mice xenografted with the human midgut carcinoid GOT1. The tumours in 22 out of 23 animals given therapeutic amounts showed dose-dependent, rapid complete remission. The diagnostic amount (0.5 MBq [177 Lu-DOTA0 -Tyr3 ]-octreotate) did not influence tumour growth and was rapidly excreted. In contrast, the therapeutic amount (30 MBq [177 Lu-DOTA0 -Tyr3 ]-octreotate) induced rapid tumour regression and entrapment of177 Lu so that the activity concentration of177 Lu remained high, 7 and 13 days after injection. The entrapment phenomenon increased the absorbed dose to tumours from 1.6 to 4.0 Gy MBq−1 and the tumours in animals treated with 30 MBq received 120 Gy. Therapeutic amounts of [177 Lu-DOTA0 -Tyr3 ]-octreotate rapidly induced apoptosis and gradual development of fibrosis in grafted tumours. In conclusion, human midgut carcinoid xenografts can be cured by receptor-mediated radiation therapy by optimising the uptake of radioligand and taking advantage of the favourable change in biokinetics induced by entrapment of radionuclide in the tumours.British Journal of Cancer (2005) 93, 1144–1151. doi:10.1038/sj.bjc.6602845 www.bjcancer.com Published online 25 October 2005 [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF